A Phase 1, Single Ascending Dose Trial to Establish the Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Monotherapy and of E10030 Given in Combination With Lucentis 0.5 Mg/Eye in Subjects With Neovascular Age-Related Macular Degeneration

Trial Profile

A Phase 1, Single Ascending Dose Trial to Establish the Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Monotherapy and of E10030 Given in Combination With Lucentis 0.5 Mg/Eye in Subjects With Neovascular Age-Related Macular Degeneration

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2014

At a glance

  • Drugs Pegpleranib (Primary) ; Ranibizumab
  • Indications Age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors OphthoTech Corporation
  • Most Recent Events

    • 21 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top